1	Relative vaccine effectiveness (rVE) of mRNA COVID-19 boosters in people aged
2	at least 75 years in the UK vaccination programme, during the Spring-Summer
3	(monovalent vaccine) and Autumn-Winter 2022 (bivalent vaccine) booster campaigns: a
4	prospective test negative case-control study
5	Dr Anastasia Chatzilena PhD ⁺ , Engineering Mathematics, University of Bristol, Bristol, UK
6	Dr Catherine Hyams PhD [†] , Population Health Sciences, University of Bristol, Bristol, UK
7	Dr Rob Challen PhD, Engineering Mathematics, University of Bristol, Bristol, UK
8	Dr Robin Marlow PhD, Population Health Sciences, University of Bristol, Bristol, UK
9	Ms Jade King MSc, Clinical Research and Imaging Centre, UHBW NHS Trust, Bristol, UK
10 11	Mr David Adegbite BSc, Bristol Vaccine Centre, Population Health Sciences, University of Bristol, Bristol, UK
12 13	Ms Jane Kinney BSc, Bristol Vaccine Centre, Population Health Sciences, University of Bristol, Bristol, UK
14 15	Ms Madeleine Clout BSc, Bristol Vaccine Centre, Population Health Sciences, University of Bristol, Bristol, UK
16 17	Prof Nick Maskell MD, Academic Respiratory Unit, University of Bristol, Southmead Hospital, Bristol, UK
18 19	Dr Jennifer Oliver PhD, Bristol Vaccine Centre, Population Health Sciences, University of Bristol, Bristol, UK
20 21	Professor Adam Finn PhD [†] , Bristol Vaccine Centre, Cellular and Molecular Medicine and Population Health Sciences, University of Bristol, Bristol, UK
22 23	Dr Leon Danon PhD [†] , Engineering Mathematics, University of Bristol, Bristol, UK (Corresponding Author)
24	The Avon CAP Research Group
25	† These authors contributed equally, and should be considered co-first or last authors
26	

27	Corresponding A	thor: Leon Danon, PhD	
28		Engineering Mathematics, University of Bristol	
29		University Walk	
30		Bristol BS8 1TW	
31		United Kingdom	
32		+44(0)117 455 7828	
33		l.danon@bristol.ac.uk	
34			
35			
36			
37	Keywords: CC	VID-19, SARS-CoV-2, respiratory infection, vaccination	

38 ABSTRACT (245/250 words)

39 Background

- 40 Understanding the relative vaccine effectiveness (rVE) of new COVID-19 vaccine formulations
- 41 against SARS-CoV-2 infection is an urgent public health priority. A precise analysis of the rVE
- 42 of monovalent and bivalent boosters given during the 2022 Spring-Summer and Autumn-Winter
- 43 campaigns, respectively, in a defined population has not been reported.
- 44 Aim
- 45 We therefore assessed rVE against hospitalisation for the Spring-Summer (fourth vs third
- 46 monovalent mRNA vaccine doses) and Autumn-Winter (fifth BA.1/ancestral bivalent vs fourth
- 47 monovalent mRNA vaccine dose) boosters.

48 Methods

49 A prospective single-centre test-negative design case-control study of \geq 75 year-olds hospitalised

50 with COVID-19 or other acute respiratory disease. We conducted regression analyses controlling

- 51 for age, sex, socioeconomic status, patient comorbidities, community SARS-CoV-2 prevalence,
- 52 vaccine brand and time between baseline dose and hospitalisation.

53 **Results**

- 54 682 controls and 182 cases were included in the Spring-Summer booster analysis; 572 controls
- and 152 cases for the Autumn-Winter booster analysis. A monovalent mRNA COVID-19
- vaccine as fourth dose showed rVE 46.6% (95% confidence interval [CI] 13.9-67.1) versus those

- 57 not fully boosted. A bivalent mRNA COVID-19 vaccine as fifth dose had rVE 46.7% (95%CI
- 58 18-65-1), compared to a fourth monovalent mRNA COVID-19 vaccine dose.

59 Conclusions

- 60 Both fourth monovalent and fifth BA.1/ancestral mRNA bivalent COVID-19 vaccine doses
- 61 demonstrated benefit as a booster in older adults. Bivalent mRNA boosters offer similar
- 62 protection against hospitalisation with Omicron infection to monovalent mRNA boosters given
- 63 earlier in the year. These findings support immunisation programmes in several European
- 64 countries that advised the use of BA.1/ancestral bivalent booster doses.

65 INTRODUCTION

Following the emergence of wild-type SARS-CoV-2 and circulation of antigenically distinct 66 67 variants, large-scale vaccination programmes were implemented to reduce overall COVID-19 68 morbidity and mortality. In the UK, several COVID-19 vaccines received rapid regulatory 69 authorisation: the vaccines used initially were the monovalent mRNA vaccine BNT162b2 70 (Cominarty®) and the ChAdOx1 (Vaxzevria®) replication-deficient simian adenovirus vector 71 vaccine, with mRNA-1273 (Spikevax®) vaccine incorporated a few months later. These three 72 COVID-19 vaccines were used in the primary campaign in the UK which began in December 73 2020, using initially an extended interval between first and second doses equal to 12 weeks, to 74 prioritise first dose administration. The mRNA vaccines were offered as boosters 6-months after 75 completion of the primary course, from September 2021 for adults aged \geq 50 years (y) and those 76 in clinical risk groups, extending to all adults in November 2021. A fourth dose of an mRNA 77 vaccine was offered from March 2022 and prioritised the most vulnerable: all adults aged \geq 75 y, 78 and those in clinical risk groups[1]. A third priming vaccine dose had already been offered to 79 immunosuppressed individuals, so that for them, the autumn 2021 and spring 2022 boosters were 80 generally their fourth and fifth doses, respectively. The COV-Boost study indicated that a fourth-81 dose COVID-19 mRNA vaccination boosts immune responses[2], and an observational study 82 showed three or four-dose vaccine effectiveness (VE) against hospitalisation of 60.9-62.1% 83 against BA.4 or BA.5 variants which emerged during spring 2022 and 50.1% against BA.2 when 84 compared to two-doses received ≥ 25 weeks earlier[3]. These initial COVID-19 vaccines were 85 developed against wild-type virus and provided significant protection against infection, 86 hospitalisation, severe disease and death[4-8]. However, VE has been eroded progressively both

by waning of immune-protection over time and emergence of SARS-CoV-2 variants of concern
(VOC) (Alpha, Delta, Omicron) which show immune escape, [9–12].

89

90	In summer 2022, the UK Medicines & Healthcare products Regulatory Agency (MHRA)
91	approved two new bivalent booster vaccines which were developed in response to concerns
92	about such viral evolution and escape. The Moderna bivalent vaccine (Spikevax® bivalent
93	Original/Omicron) was approved on 15th August 2022, followed quickly by Pfizer/BioNTech
94	bivalent vaccine (Comirnaty® Original/Omicron BA.1) approval on 3rd September 2022[13,14]
95	and they were distributed during autumn 2022, being the fifth dose offered in the UK. The
96	Moderna vaccine contains 25mcg of mRNA coding for the spike protein of the ancestral strain
97	and 25mcg of mRNA against Omicron (BA.1) and the Pfizer BioNTech vaccine contains 15mcg
98	of mRNA directed against the ancestral strain and 15mcg of mRNA against Omicron (BA.1).
99	Early immunogenicity studies suggest bivalent mRNA boosters induce similar or higher
100	neutralising antibody levels against Omicron sub-variants and other VOCs compared to
101	monovalent mRNA boosters[15–19].

102

SARS-CoV-2 infection incidence remains high[20], whilst determining whether patients who
test SARS-CoV-2 positive have COVID-19 has become increasingly challenging using studies
relying on data linkage methodology. Additionally, comparison between vaccinated individuals
and those who have not received any COVID-19 vaccine dose cannot be performed, as 78.2% of
the adult population in the UK have received at least 2 doses or had prior exposure to SARSCoV-2: thus even unvaccinated individuals have some immunity to SARS-CoV-2. There remains

- 109 limited evidence[10,15,21] of bivalent vaccines' clinical effectiveness when compared to
- 110 monovalent formulations because the different vaccine rollout timings make a direct comparison
- 111 of the vaccines impossible. Acknowledging this constraint, we undertook a test-negative design
- 112 (TND) case control study comparing SARS-CoV-2 positive and negative acute lower respiratory
- 113 tract disease (aLRTD) patients, implementing two separate analyses to assess the protection
- against SARS-CoV-2 hospitalisation provided by an additional monovalent or BA.1/ancestral
- 115 bivalent mRNA vaccine dose relative to those who had not received the respective doses,
- focusing on \geq 75y olds who were the main target group in the spring 2022 booster programme.
- 117 Given the different rollout timings of the two vaccine formulations, the analyses refer to two
- 118 distinct study time periods with different subvariants circulating.

119 METHODS

120 Study design and conduct

121	We estimated the relative vaccine effectiveness (rVE) of monovalent and bivalent mRNA
122	vaccines against hospitalisation in Bristol, within the study population consisting of adults
123	admitted to North Bristol and University Hospitals Bristol and Weston NHS Trusts [AvonCAP:
124	ISRCTN17354061] between 4th April 2022 and 30th July 2022 (the period following the
125	initiation of distribution of fourth dose of monovalent mRNA vaccines), and between 21st
126	September 2022 and 23rd January 2023 (the period following the initiation of distribution of
127	bivalent mRNA vaccines) inclusive. During the first study period BA.4, BA.2 and BA.5 were the
128	main Omicron sub-lineages identified in COVID-19 cases in England, while the dominant sub-
129	lineages identified during the second study period were BA.5, BA.4.6, BQ.1, CH1.1, XBB
130	recombinant lineage and its mutation XBB.1.5 (Supplementary Data S2) [22]. The study
131	population consisted of patients with signs/symptoms of respiratory infection, aged $\geq 18y$ at the
132	time of hospitalisation[23]. Study eligible cases and controls eligible were identified from the
133	medical admission list, and data were collected from medical records using REDCap
134	software[24]. All data collection was undertaken by individuals not involved in analysis and
135	blinded to results, following the same procedures for both cases and controls. Vaccination
136	records for every study participant were obtained from linked hospital and GP records, including
137	vaccine brand and date of administration with data collection performed by individuals blinded
138	to participants' SARS-CoV-2 test results[25].

139

140

141

142 Case definition and exclusions

143	We included patients with ≥ 2 signs of acute respiratory disease (cough, fever, dyspnoea,
144	tachypnoea, increased/discoloured sputum expectoration, pleurisy, clinical or radiological
145	findings suggestive of acute disease) or a confirmed clinical/radiological diagnosis of
146	aLRTD[25]. Patients hospitalised with aLRTD and positive admission SARS-CoV-2 test using
147	the UK Health Security Agency (UKHSA) diagnostic assay in use at the time were classified as
148	cases; those with aLRTD and negative SARS-CoV-2 result were classified as controls. Eligible
149	controls could have multiple hospitalisations, provided subsequent admissions were >7 days
150	following previous discharge. We included only the first COVID-19 admission for each case.
151	
152	We excluded patients whose admission date was >10 days after symptom onset date (to avoid
153	including potentially false negative admission SARS-CoV-2 tests), and those with a confirmed
154	previous SARS-CoV-2 infection based on any positive test result that could be found in local

and/or national clinical care record database, including linkage through the UKHSA national

testing system. Patients who had received 2 vaccine doses or fewer at the time of admission werealso excluded (Supplementary Data S1).

158

In order to make a side-by-side evaluation of the effectiveness of the different booster vaccine
formulations, we restricted both analyses to individuals aged ≥75y, since the Joint Committee on
Vaccination and Immunisation (JCVI) advised targeting COVID-19 booster vaccines during

162	spring-summer towards those at highest risk of severe disease; those aged ≥75y and residents in
163	long-term care facilities (LTCFs)[1], while in Autumn-Winter 2022 the offer was extended,
164	including those aged \geq 50y and frontline health and social care workers [26]. Therefore, patients
165	< 75y were excluded from analyses.

166

167 Exposure definition

168 This analysis aims to measure the protection offered by an additional dose of monovalent

169 (Original 'wild-type' mRNA vaccine, Pfizer-BioNTech [Comirnaty®] or Moderna [Spikevax®])

and bivalent (Original 'wild-type'/Omicron BA.1 mRNA vaccine, Pfizer-BioNTech

171 [Comirnaty®] or Moderna [Spikevax®]) vaccine within 3 months after vaccination, each

172 compared with those who had not received the respective boosters, side by side, during SARS-

173 CoV-2 Omicron variant dominance. The Spring-Summer monovalent booster analysis

174 (admissions 04/04/22-30/07/22) compares the fourth dose of monovalent given as a booster

175 (21/03/22-07/08/22) in the UK, to the third dose of monovalent vaccine during Autumn-Winter

176 2021 (16/09/21-14/02/22). By the end of this study period, the vaccine uptake in the UK in the

177 over 75s was 74.3% for spring 2022 booster and 93.5% for 3 doses (cf. median vaccine uptake of

178 13.6% and 84.2% respectively in EU/EEA countries in over 60 year olds, based on available data

179 [27]). The Autumn-Winter bivalent booster analysis (admissions 21/09/22-23/01/23) compares

180 the fifth dose of vaccine, with the bivalent formulation given as a booster (07/09/22-12/02/23) to

181 the fourth dose of monovalent vaccine in Spring-Summer 2022 (21/03/22-07/08/22). The vaccine

uptake in individuals aged \geq 75y by the end of this study period was 83.5% for autumn 2022

183	booster and 74.9% for spring 2022 booster (cf. median vaccine uptake of 2.2% and 35.1%
184	respectively in EU/EEA countries in over 60 year olds based on available data [27]).

185

186	For the Spring-Summer monovalent booster analysis, individuals were defined as boosted with a
187	monovalent vaccine if they had received three doses of any monovalent vaccine combination and
188	a fourth dose of monovalent vaccine during the Spring-Summer 2022 vaccination programme,
189	and no more than three months prior to their admission, and as not fully boosted only if they had
190	received two doses of any vaccine combination followed by a third dose of monovalent vaccine
191	during Autumn-Winter 2021. For the Autumn-Winter bivalent booster analysis, individuals were
192	defined as boosted with a BA.1/ancestral bivalent vaccine if they had received four doses of any
193	vaccine combination plus a fifth bivalent dose during Spring-Summer 2022 vaccination
194	programme and no more than three months prior to their admission, and as not fully boosted if
195	they had received three doses of any vaccine combination plus a fourth monovalent dose during
196	Autumn-Winter 2022. In both analyses, we define those having received the most recent dose
197	with >7 days having elapsed between the vaccine and symptom onset as immunised
198	(Supplementary Data S1).

199

Individuals who received a third vaccine dose in Autumn-Winter 2021, a fourth dose in SpringSummer 2022 and a fifth dose in Autumn-Winter 2022, are those who had received two doses as
the primary vaccination regimen before and during Spring-Summer 2021. However, individuals
with severe immunosuppression around the time of their first or second vaccine doses were
offered an additional primary dose (third dose) before any booster doses. As a result, they were

205	offered a fourth vaccine dose in Autumn-Winter 2021, a fifth dose in Spring-Summer 2022 and a
206	sixth dose in Autumn-Winter 2022 (Figure 1, Supplementary Data S2). Since this population
207	almost exclusively comprised of immunosuppressed individuals we perform additional
208	sensitivity analyses including those individuals who had received three doses as their primary
209	vaccination regimen in both comparisons.
210	
211	Outcomes
212	We assessed the additional protection provided by a fourth dose of mRNA monovalent vaccine
213	and a fifth dose of BA.1/ancestral bivalent vaccine as boosters against the primary endpoint of
214	hospital admission with a positive admission SARS-CoV-2 test and either a clinical or
215	radiological aLRTD diagnosis or aLRTD signs/symptoms compared to that provided by three or
216	four doses of the monovalent formulations of the vaccines, respectively.
217	
218	Statistical Analysis
219	Demographic, clinical characteristics and other factors that may affect the exposure (vaccination
220	status) or outcome (hospital admission) were compared between cases and controls for both
221	comparisons, between monovalent vaccine boosted and not fully boosted, and between boosted
222	with a bivalent vaccine and not fully boosted, using Fisher exact tests (categorical variables),
223	two-sided Kolmogorov-Smirnov tests (continuous variables) and Wilcoxon rank-sum tests (score
224	variables).

225

226	Under TND assumptions, we estimate the odds ratio of testing SARS-CoV-2 positive among
227	patients boosted with a monovalent vaccine versus those not fully boosted (rOR) and define rVE
228	as (1–rOR)×100. Similarly, we estimated rVE of bivalent booster, comparing the odds of testing
229	positive for SARS-CoV-2 among patients boosted with a bivalent vaccine versus those not fully
230	boosted. This was done using univariable logistic regression (Univariable Logistic Regression
231	Model). Differences in the timing of third/fourth dose and rollout timings of different vaccine
232	brands could introduce unobserved biases, confounding results in both comparisons. To mitigate
233	these, we performed multivariable logistic regression analyses adjusting for time between
234	baseline vaccine dose (third dose for the Spring-Summer monovalent booster, and fourth dose
234 235	baseline vaccine dose (third dose for the Spring-Summer monovalent booster, and fourth dose for the Autumn-Winter bivalent booster analysis) and admission (in days), vaccine brand [binary
235	for the Autumn-Winter bivalent booster analysis) and admission (in days), vaccine brand [binary
235 236	for the Autumn-Winter bivalent booster analysis) and admission (in days), vaccine brand [binary variable], age, sex, Index of Multiple Deprivations (IMD) decile rank and Charlson comorbidity

240

We also conducted sensitivity analyses, matching cases and controls using propensity score
balancing using logistic regression to define propensity score, and nearest neighbour matching.
Matching variables included age, sex, CCI and IMD, LTCF residency status and presence of preexisting respiratory disease, and likelihood of vaccine receipt (Matched Conditional Logistic
Regression Model). Matching by elapsed time since baseline vaccine dose/brand was not
performed to avoid introducing bias[28]. Time since baseline vaccine dose/ brand is affected by

dose of last vaccine received; each booster was deployed ≥4 months after the previous COVID-
19 booster programme (Figure 1), with different programmes using different proportions of each
vaccine brand. As additional sensitivity analysis, we included individuals who had received three
doses as primary vaccination regimen, adjusting for the number of primary doses [binary
variable], using the same methods for both comparisons.
Statistical analyses were performed with R v4.0.2. Missing data were limited to the IMD variable
and accounted for <1%; no imputation was performed; all analyses only included participants
with complete data. Statistical significance was defined using a 2-sided significance level of
α=0.05.
Ethics and permissions
The Health Research Authority Research Ethics Committee (East of England, Essex),
REC20/EE/0157 approved this study, including using Section 251 of the 2006 NHS Act under
Confidentiality Advisory Group authorisation.
Role of the funding source
This study was conducted as a collaboration between The University of Bristol (study sponsor)
and Pfizer (study funder). The study funder did not undertake any data collection, data analysis

266 or manuscript preparation.

267 **RESULTS**

268	During the periods evaluated, 9,868 adult aLRTD hospitalisations occurred in Bristol, UK, while
269	the Omicron variant was dominant[22,29,30]. In the Spring-Summer booster, 864 admissions of
270	\geq 75y old patients hospitalised with SARS-CoV-2 aLRTD were eligible for this analysis: median
271	patient age was 85y (IQR 80-89), 403 individuals (46%) were male, median CCI was 5 (IQR 4-
272	6) with no significant differences in patient age and sex between SARS-CoV-2 positive and
273	negative aLRTD, while there was a statistically significant difference in their ethnicity, LTCF
274	residency status, smoking and presence of pre-existing respiratory disease and chronic
275	obstructive pulmonary disease (Figure 1, Table 1). In the Autumn-Winter booster, 884
276	admissions of \geq 75y old patients were eligible with no significant differences in age, sex and
277	LTCF residency status between SARS-CoV-2 positive and negative aLRTD, while differences in
278	ethnicity, smoking and dementia status were statistically significant (Figure 1, Table 2). In both
279	comparisons, there were no significant differences in patient demographics and health status
280	between vaccination groups (Supplementary Data S3, S4).
281	
282	In the Spring-Summer booster analysis, of the 182 SARS-CoV-2 cases, 78 (43%) received a

In the Spring-Summer booster analysis, of the 182 SARS-Cov-2 cases, 78 (43%) received a fourth monovalent vaccine dose and 104 (57%) received a third monovalent vaccine dose, while 413 of 682 controls (61%) received a fourth monovalent vaccine dose and 269 (39%) received a third monovalent vaccine dose. All those vaccinated with a fourth monovalent dose were hospitalised \leq 3 months after their vaccination and 98% of those who had received only 3 doses were hospitalised \geq 3 months after their vaccination (Supplementary Data S3). The unadjusted rVE was 51.2% (95%CI 32.1-65) and after adjustment, rVE was 46.6% (95%CI 13.9-67.1).

Matched conditional logistic regression rVE was 52% (95%CI 20·9-70·9) (Table 3). Sensitivity analysis including individuals with three doses as primary vaccination regimen (who make up 8.5% of cases and 5.8% of controls) resulted in lower rVE estimates compared with results from the main analysis (Table 3, Supplementary Data S5, S6, S9).

293

294 In the Autumn-Winter booster analysis, of the 152 SARS-CoV-2 cases, 100 (66%) received a 295 fifth BA.1/ancestral bivalent vaccine dose and 52 (34%) received a fourth monovalent vaccine 296 dose, while 572 of 732 (78%) controls received a fifth bivalent vaccine dose and 160 (22%) 297 received a fourth monovalent vaccine dose. All those vaccinated with a fifth BA.1/ancestral 298 bivalent vaccine dose were hospitalised ≤ 3 months after their vaccination and 97% of those who 299 had received only 3 doses were hospitalised >3 months after their vaccination (Supplementary 300 Data S4). The unadjusted rVE was 46.2% (95%CI 21.1-63) and after adjustment, rVE was 301 46.7% (95%CI 18-65.1). Matched conditional logistic regression rVE was 48.8% (95%CI 19.8-302 67.3) (Table 4). The inclusion of individuals with three doses as primary vaccination regimen 303 (who make up 3.8% of cases and 6.9% of controls) produced estimates comparable with results 304 from the main analysis (Table 4, Supplementary Data S7, S8, S10).

305 **DISCUSSION**

306 In this analysis, we consider the public health implications of monovalent and BA.1/ancestral 307 bivalent vaccine implementation, focusing on people aged \geq 75y; a high-risk group which was a 308 primary target for the UK vaccination programme. Although COVID-19 vaccines have been 309 shown to be effective against severe COVID-19 disease[4,31,32], it has not been possible to 310 compare the effectiveness of monovalent boosters directly with BA.1/ancestral bivalent booster 311 doses of mRNA COVID-19 vaccines in defined populations, because bivalent formulations 312 rapidly and entirely replaced monovalent formulations in the most recent booster programmes. In 313 this ongoing prospective study, we undertake a sequential sub-analysis of the two vaccines given 314 as boosters during two booster programmes in the same calendar year, providing evidence that 315 monovalent vaccine (Original 'wild-type' Comirnaty® and Spikevax®) and BA.1/ancestral 316 mRNA bivalent vaccine (Original 'wild-type'/Omicron BA.1 Cominarty® and SpikeVax®) 317 within three months after vaccination provided similar additional protection compared to that 318 afforded by waned previous doses against hospitalisation from Omicron SARS-CoV-2 sub-319 variants in older individuals, given unknown effects of the different subvariant circulating during 320 the distribution of the two vaccine formulations (Supplementary Data 2 C).

321

Specifically, we estimated that a fourth monovalent mRNA vaccine dose within three months
after vaccination, was associated with a 46.6% (95%CI 13.9-67.1) additional protection against
hospitalisation compared to waned three doses, in individuals ≥75y, during Omicron BA.2,
BA.4, BA.5 lineage dominance. Within three months of receiving a fifth bivalent mRNA vaccine
dose, it is estimated to provide 46.7% (95%CI 18-65.1) additional protection against

hospitalisation compared to waned four doses, in the same \geq 75y age group, even when assessed during a period when heterologous variants were circulating since BA.5, BA.4.6, BQ.1 and CH1.1 lineages, the XBB recombinant lineage and its mutation XBB.1.5 accounted for most of the identified cases in England (Supplementary Data 2 C) [22].

331

332 Although our results demonstrate that both vaccine formulations combined in these booster 333 programmes had benefits when used as boosters, we have insufficient case numbers to draw 334 conclusions about individual vaccine brands or directly compare them. Importantly, this analysis 335 is restricted to individuals \geq 75y old, with 97-98% of not fully boosted individuals in our sample 336 potentially having waned vaccine-induced immunity since they received their last dose more 337 than 3 months prior to admission(Supplementary Data S2, S3). Given that this study has a short 338 follow up period after the administration of the two boosters, we cannot provide estimates by 339 time since vaccination; nonetheless it presents encouraging evidence of similar benefit of 340 monovalent and bivalent boosters in older adults, up to three months after vaccination. Older 341 adults are at increased risk of severe disease, and protection may wane faster[33]; older adults 342 were therefore targeted in the UK Spring-Summer 2022 and Autumn-Winter 2022 COVID-19 343 booster programmes. Our analysis based on the inclusion of individuals with severely weakened 344 immune systems who were eligible for three primary doses in our basic comparisons, suggests 345 that both vaccine formulations may offer some additional protection, however given that they 346 account for <7% of our sample we have insufficient statistical power to draw firm conclusions.

348 Vaccination against SARS-CoV-2 is independently associated with lower COVID-19 349 severity [4,31,32], and vaccines have been an important disease modifier during the pandemic. 350 Our estimates suggest that the bivalent boosters provided similar protection as monovalent 351 boosters in a real-world setting where the landscape of COVID-19 variants is constantly 352 changing: results concordant with early evidence suggesting neutralising antibody titres induced 353 against Omicron by a bivalent booster dose were not higher than following a monovalent booster 354 dose in small studies [16,17]. Our results are concordant with a recent UKHSA analysis [34] 355 which estimated the incremental protection conferred by a fourth monovalent dose compared to 356 waned third dose was 58.8% (95%CI 54-63%), while the additional protection of BA.1/ancestral 357 mRNA bivalent vaccines relative to those with ≥ 2 doses and waned protection was 57% (95%CI 358 48-65%), during the same time period as our analysis.

359

360 Since the study took place over the course of two different time periods, the interpretation of 361 these sequential analyses of the two vaccine formulations has to take into account the different 362 variants circulating[22,29,30]. In England, the Omicron variants BA.2, BA.4, BA.5 were the 363 main circulating variants during the study period of the monovalent booster, and were replaced 364 by BA.4 and BA.5 descendent sub-lineages(BA.4.6, BQ.1), CH1.1, XBB and XBB.1.5 lineage 365 during the study period of the BA.1/ancestral bivalent boosters, with BA.5 being the only 366 subvariant in common. Consequently, in this study, the performance of the BA.1/ancestral 367 bivalent booster was not evaluated against homologous subvariants but against BA.4/5 which 368 show further immune escape beyond that observed for BA.1. Currently, there is no evidence that 369 Omicron BA.4-related sublineages, Omicron BA.5-related sublineages, CH1.1 and XBB 370 recombinant-related sublineages, which appeared during the study period of the BA.1/ancestral

mRNA bivalent boosters, cause more severe disease. The impact of these lineages on the
effectiveness of the BA.1/ancestral mRNA bivalent formulation has not yet been studied in
detail.

374

375 The TND has been described previously, along with its advantages and limitations [12,25,35], 376 and our analysis has some important additional strengths and limitations. The strength of our 377 approach is the focus on using real-world data, while accounting for the potential effects of 378 LTCF residency status, socioeconomic status and comorbidities. By limiting our analysis to 379 boosted individuals only, our analysis sidesteps the potentially unfair comparisons between 380 populations that have followed UK COVID-19 vaccine recommendations and unvaccinated 381 populations that may display other idiosyncratic behaviours. We also utilised symptom onset 382 date to define illness start time and are able to confirm that there is no difference in time since 383 vaccination between the case and control groups compared. We, therefore, define illness onset 384 relative to both vaccination and hospitalisation date accurately, without relying on positive test 385 date (which may vary widely), eliminating this source of bias or misclassification. All patients 386 were hospitalised with acute respiratory illness, so these results are unlikely to be subject to 387 significant bias caused by admission for other causes (i.e., incidental COVID-19 disease). Most 388 notably, our estimates for the effect of individual vaccines are underpowered, due to small 389 patient numbers in our cohort during the phases of the UK vaccination programme and study 390 periods. We are unable to assess additional protection against other markers of disease severity, 391 such as admission to intensive care or requirement for respiratory support, due to the small 392 number of eligible admissions in this time period. This analysis does not measure rVE in 393 individuals who were not hospitalised or were asymptomatic, so we cannot determine protection

394	against asymptomatic disease or transmission. Treatment biases may result in community-based
395	treatment, death before admission, or patients may otherwise not be referred to hospital. We note
396	that this cohort, whilst broadly representative of the UK population, was predominantly
397	Caucasian and the studied vaccines may have different effectiveness in individuals from other
398	ethnic backgrounds.

- 400 In this prospective study, we provide evidence that autumn BA.1/ancestral mRNA bivalent
- 401 COVID-19 boosters offered similar augmentation of protection against Omicron hospitalisation
- 402 to that induced by spring monovalent mRNA boosters in 2022. These findings support
- 403 immunisation programmes in the UK and several European countries, that advised the use of
- 404 BA.1/ancestral mRNA bivalent booster doses in high risk individuals.

405 FIGURE LEGENDS

406

407 Figure One: Study Flow Diagram

- 408 (A) Inclusion and exclusion criteria in the cohort. The left panel describes the Spring-Summer
- 409 monovalent booster analysis; of the 182 SARS-CoV-2 positive individuals, 78 were vaccinated
- 410 with 4th dose monovalent mRNA vaccine, and 104 were vaccinated with 3rd dose monovalent
- 411 mRNA vaccine. Of the 682 SARS-CoV-2 negative individuals admitted, 413 were vaccinated
- 412 with 4th dose monovalent mRNA vaccine and 269 were vaccinated with 3rd dose monovalent
- 413 mRNA vaccine. The right panel describes the Autumn-Winter bivalent booster analysis; of the
- 414 152 SARS-CoV-2 positive individuals, 100 were vaccinated with 5th dose bivalent mRNA
- 415 vaccine, and 52 were vaccinated with 4th dose monovalent mRNA vaccine. Of the 732 SARS-
- 416 CoV-2 negative individuals admitted, 572 were vaccinated with 5th dose bivalent mRNA
- 417 vaccine and 160 were vaccinated with 4th dose monovalent mRNA vaccine. (B) Study timeline

418 Data Sharing

419	The data used in this study are sensitive and cannot be made publicly available without
420	breaching patient confidentiality rules. The data dictionary is therefore unavailable.
421	
422	
423	
424	
425	
426	
427	
428	
429	
430	
431	
432	
433	
434	
435	
436	
437	
438	
439	
440	
441	
442	
443	
444	
445	
446	
447	
448	
449	
450	

452 **REFERENCES**

- 453 1. Joint Committee on Vaccination and Immunisation (JCVI) statement on COVID-19
- 454 vaccinations in 2022: 21 February 2022. https://www.gov.uk/government/publications/joint-
- 455 committee-on-vaccination-and-immunisation-statement-on-covid-19-vaccinations-in-2022/joint-
- 456 committee-on-vaccination-and-immunisation-jcvi-statement-on-covid-19-vaccinations-in-2022-457 21-february-2022
- 457 21-february-2022.
- 458 2. Munro APS, Feng S, Janani L, Cornelius V, Aley PK, Babbage G, et al. Safety,
- 459 immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given
 460 as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third
- 461 dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial. Lancet
- 462 Infect Dis. 2022;22:1131–41.
- 463 3. Kirsebom FCM, Andrews N, Stowe J, Groves N, Chand M, Ramsay M, et al. Effectiveness of
- the COVID-19 vaccines against hospitalisation with Omicron sub-lineages BA.4 and BA.5 in England Lancet Reg Health Eur 2022:22
- 465 England. Lancet Reg Health Eur. 2022;23.
- 466 4. Lauring AS, Tenforde MW, Chappell JD, Gaglani M, Ginde AA, McNeal T, et al. Clinical
 467 severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and
 468 alpha SARS-CoV-2 variants in the United States: prospective observational study. BMJ.
 469 2022;376:e069761.
- 5. Nordström P, Ballin M, Nordström A. Risk of infection, hospitalisation, and death up to 9
 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study
 in Sweden. Lancet Lond Engl. 2022;399:814–23.
- 473 6. Chung H, He S, Nasreen S, Sundaram ME, Buchan SA, Wilson SE, et al. Effectiveness of
- BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and
 severe covid-19 outcomes in Ontario, Canada: test negative design study. BMJ. 2021;374:n1943.
- 476 7. Andrews N, Stowe J, Kirsebom F, Toffa S, Sachdeva R, Gower C, et al. Effectiveness of
- 477 COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in
 478 England. Nat Med. 2022;28:831–7.
- 8. Tseng HF, Ackerson BK, Luo Y, Sy LS, Talarico CA, Tian Y, et al. Effectiveness of mRNA1273 against SARS-CoV-2 Omicron and Delta variants. Nat Med. 2022;28:1063–71.
- 9. Britton A, Fleming-Dutra KE, Shang N, Smith ZR, Dorji T, Derado G, et al. Association of
 COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection by Time Since Vaccination
 and Delta Variant Predominance. JAMA. 2022;327:1032–41.
- 484 10. Lin D-Y, Gu Y, Xu Y, Wheeler B, Young H, Sunny SK, et al. Association of Primary and
 485 Booster Vaccination and Prior Infection With SARS-CoV-2 Infection and Severe COVID-19
 486 Outcomes. JAMA. 2022;328:1415–26.

487 11. Ferdinands JM, Rao S, Dixon BE, Mitchell PK, DeSilva MB, Irving SA, et al. Waning 2-

488 Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency

- 489 Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of
- 490 Delta and Omicron Variant Predominance VISION Network, 10 States, August 2021-January
- 491 2022. MMWR Morb Mortal Wkly Rep. 2022;71:255–63.
- 492 12. Andrews N, Tessier E, Stowe J, Gower C, Kirsebom F, Simmons R, et al. Duration of
- 493 Protection against Mild and Severe Disease by Covid-19 Vaccines. N Engl J Med.
- 494 2022;386:340–50.
- 495 13. Regulatory approval of Spikevax bivalent Original/Omicron booster vaccine.
- 496 https://www.gov.uk/government/publications/regulatory-approval-of-spikevax-bivalent-
- 497 originalomicron-booster-vaccine [Internet]. [cited 2022 Nov 28]. Available from:
- 498 https://www.gov.uk/government/publications/regulatory-approval-of-covid-19-vaccine-moderna
- 499 14. Regulatory approval of Pfizer/BioNTech bivalent Original/Omicron booster vaccines.
- 500 https://www.gov.uk/government/publications/regulatory-approval-of-pfizerbiontech-bivalent-
- 501 originalomicron-booster-vaccine [Internet]. [cited 2022 Nov 28]. Available from:

 $502 \qquad https://www.gov.uk/government/publications/regulatory-approval-of-pfizerbiontech-bivalent-biva$


- 503 originalomicron-booster-vaccine
- 504 15. Chalkias S, Harper C, Vrbicky K, Walsh SR, Essink B, Brosz A, et al. A Bivalent Omicron505 Containing Booster Vaccine against Covid-19. N Engl J Med. 2022;387:1279–91.
- 506 16. Collier AY, Miller J, Hachmann NP, McMahan K, Liu J, Bondzie EA, et al. Immunogenicity
 507 of the BA.5 Bivalent mRNA Vaccine Boosters. bioRxiv. 2022;2022.10.24.513619.
- 17. Wang Q, Bowen A, Valdez R, Gherasim C, Gordon A, Liu L, et al. Antibody responses to
 Omicron BA.4/BA.5 bivalent mRNA vaccine booster shot. bioRxiv. 2022;2022.10.22.513349.
- 510 18. Davis-Gardner ME, Lai L, Wali B, Samaha H, Solis D, Lee M, et al. mRNA bivalent booster
 511 enhances neutralization against BA.2.75.2 and BQ.1.1. bioRxiv. 2022;2022.10.31.514636.
- 512 19. Kurhade C, Zou J, Xia H, Liu M, Chang HC, Ren P, et al. Low neutralization of SARS-CoV-
- 513 2 Omicron BA.2.75.2, BQ.1.1, and XBB.1 by parental mRNA vaccine or a BA.5-bivalent
 514 booster. Nat Med. 2022;1–1.
- 515 20. England Summary | Coronavirus (COVID-19) in the UK. https://coronavirus.data.gov.uk.
 516 2023.
- 517 21. Andersson NW, Thiesson EM, Baum U, Pihlström N, Starrfelt J, Faksová K, et al.
- 518 Comparative effectiveness of the bivalent BA.4-5 and BA.1 mRNA-booster vaccines in the
- 519 Nordic countries [Internet]. medRxiv; 2023 [cited 2023 Jun 26]. p. 2023.01.19.23284764.
- 520 Available from: https://www.medrxiv.org/content/10.1101/2023.01.19.23284764v1

521 22. SARS-CoV-2 variants of concern and variants under investigation in England: technical
 522 briefing 52. Available from:

- https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file
 /1152143/variant-technical-briefing-52-21-april-2023.pdf
- 525 23. Hyams C, Challen R, Begier E, Southern J, King J, Morley A, et al. Incidence of community
 526 acquired lower respiratory tract disease in Bristol, UK during the COVID-19 pandemic: A
 527 prospective cohort study. Lancet Reg Health Eur. 2022;21.
- 528 24. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data
 529 capture (REDCap)—A metadata-driven methodology and workflow process for providing
 530 translational research informatics support. J Biomed Inform. 2009;42:377–81.
- 531 25. Hyams C, Marlow R, Maseko Z, King J, Ward L, Fox K, et al. Effectiveness of BNT162b2
- and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at
 least 80 years: a test-negative, case-control study. Lancet Infect Dis. 2021;21:1539–48.
- 534 26. JCVI statement on the COVID-19 booster vaccination programme for autumn 2022: update 3
- 535 September 2022. https://www.gov.uk/government/publications/covid-19-vaccines-for-autumn-
- 536 2022-jcvi-advice-15-august-2022/jcvi-statement-on-the-covid-19-booster-vaccination-
- 537 programme-for-autumn-2022-update-15-august-2022.
- 538 27. COVID-19 Vaccine Tracker | European Centre for Disease Prevention and Control [Internet].
- [cited 2023 Jun 29]. Available from: https://qap.ecdc.europa.eu/public/extensions/COVID 19/vaccine-tracker.html#uptake-tab
- 541 28. Greenland S. Quantifying biases in causal models: classical confounding vs collider542 stratification bias. Epidemiol Camb Mass. 2003;14:300–6.
- 543 29. Lineages (raw) | COVID-19 Genomic Surveillance Wellcome Sanger Institute.
- 544 https://covid19.sanger.ac.uk/lineages/raw?p_type=line&area=E06000023&lineageView=1&line
 545 ages=A%2CB%2CB.1.177%2CB.1.1.529%2CBA.4%2CBA.5%2CBA.2&colours=7%2C3%2C
 546 0%2C6%2C2%2C4%2C1&show=B.1.1.529%2CBA.4%2CBA.5%2CBA.2.
- 30. Wright DW, Harvey WT, Hughes J, Cox M, Peacock TP, Colquhoun R, et al. Tracking
 SARS-CoV-2 mutations and variants through the COG-UK-Mutation Explorer. Virus Evol.
 2022;8:veac023.
- 550 31. Hyams C, Challen R, Marlow R, Nguyen J, Begier E, Southern J, et al. Severity of Omicron
- 551 (B.1.1.529) and Delta (B.1.617.2) SARS-CoV-2 infection among hospitalised adults: A
- prospective cohort study in Bristol, United Kingdom. Lancet Reg Health Eur. 2023;25:100556.
- 553 32. Nyberg T, Ferguson NM, Nash SG, Webster HH, Flaxman S, Andrews N, et al. Comparative
- analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron
- 555 (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. The Lancet.
- 556 2022;399:1303–12.
- 557 33. Cerqueira-Silva T, Oliveira V de A, Boaventura VS, Pescarini JM, Júnior JB, Machado TM,
- et al. Influence of age on the effectiveness and duration of protection of Vaxzevria and
- 559 CoronaVac vaccines: A population-based study. Lancet Reg Health Am. 2022;6.

- 560 34. COVID-19 vaccine surveillance report: week 5.
- $561 https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file$
- 562 /1134076/vaccine-surveillance-report-week-5-2023.pdf.
- 563 35. Chatzilena A, Hyams C, Challen R, Marlow R, King J, Adegbite D, et al. Effectiveness of
- 564 BNT162b2 COVID-19 vaccination in prevention of hospitalisations and severe disease in adults
- with SARS-CoV-2 Delta (B.1.617.2) and Omicron (B.1.1.529) variant between June 2021 and
- 566 July 2022: A prospective test negative case–control study. Lancet Reg Health Eur.
- 567 2023;25:100552.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuit It is made available under a CC-BY 4.0 International license.



ah ah a

082 387 689 - 181 - 12

n

2

2

₽ ₽ ₽

Dech